Cited by 523Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model OrganismsSirtuins and Resveratrol in Medicine

The role of cellular senescence in ageing and endocrine disease

Open access
Khosla, Sundeep, Farr, Joshua N., Tchkonia, Tamara, Kirkland, James L.·2020·Nature Reviews Endocrinology

Abstract

With the ageing of the global population, interest is growing in the 'geroscience hypothesis', which posits that manipulation of fundamental ageing mechanisms will delay (in parallel) the appearance or severity of multiple chronic, non-communicable diseases, as these diseases share the same underlying risk factor - namely, ageing. In this context, cellular senescence has received considerable attention as a potential target in preventing or treating multiple age-related diseases and increasing healthspan. Here we review mechanisms of cellular senescence and approaches to target this pathway therapeutically using 'senolytic' drugs that kill senescent cells or inhibitors of the senescence-associated secretory phenotype (SASP). Furthermore, we highlight the evidence that cellular senescence has a causative role in multiple diseases associated with ageing. Finally, we focus on the role of cellular senescence in a number of endocrine diseases, including osteoporosis, metabolic syndrome and type 2 diabetes mellitus, as well as other endocrine conditions. Although much remains to be done, considerable preclinical evidence is now leading to the initiation of proof-of-concept clinical trials using senolytics for several endocrine and non-endocrine diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41574-020-0335-y

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Immune clearance of remaining senescent cells could be especially important for older individuals or those with chronic diseases who already have high senescent cell burden.

    “This could be especially important for older individuals or those with chronic diseases, who already have a high systemic senescent cell burden24,128.”

    From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [128]

    The ‘Physiological relevance of cellular senescence’ section reports that senescent cells increase with age, and ‘Cellular senescence in ageing’ reports accelerated local or systemic accumulation across a broad range of human diseases. The paper also suggests that removing persistent senescent cells might reduce dysfunction. It does not establish that older people or people with chronic diseases generally have a high *systemic* burden, or specifically recommend immune clearance for them; ‘Markers of cellular senescence’ says it is unclear whether local measurements reflect overall burden. Page numbers are unavailable in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Osteoblasts are among the major cell types known to undergo cellular senescence during aging.

    “Osteoblasts are among the major cell types known to undergo cellular senescence during aging52,60.”
  • Cellular senescence is a driver of aging and aging-related conditions.

    “Over the past decade, mounting evidence highlights cellular senescence, a cell fate in response to diverse forms of molecular and cellular damage, as a driver of aging and aging-related conditions.”
  • Genetic and pharmacological clearance of senescent cells confers therapeutic benefits in models of myocardial infarction, atherosclerosis, diabetes, Alzheimer disease, osteoporosis, lung fibrosis, and other age-related conditions.

    “Correspondingly, genetic and pharmacological clearance of senescent cells confers therapeutic benefits in models of myocardial infarction, atherosclerosis, diabetes, Alzheimer disease, osteoporosis, lung fibrosis, and a number of other age-related conditions (12).”
  • With advancing age, senescent cells accumulate and are enriched at anatomical sites of disease, where they compromise the structure and function of multiple organs.

    “With advancing age, senescent cells accumulate and are enriched at anatomical sites of disease, where they compromise the structure and function of multiple organs.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 2

  1. [13]Tchkonia T Cellular senescence and inflammation in obesity. Obesity 17, S57 (2009).
  2. [105]US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02652052 (2016). 28792816

Cited by

Sorted by citations

Authors
Khosla, S., Farr, J. N., Tchkonia, T., & Kirkland, J. L.
Affiliations
Mayo Clinic (US)
Corresponding author
  • Khosla, Sundeep
  • Kirkland, James L.
Venue
Nature Reviews Endocrinology
Published
2020-03-11
Volume
16
Issue
5
Pages
263-275
ISSN
  • 1759-5029 (ISSN-L)
  • 1759-5037
OpenAlex
W3011207561
Cited by
523
References
160
Citations by year
2026: 61 · 2025: 88 · 2024: 111 · 2023: 74 · 2022: 84 · 2021: 71 · 2020: 33
FWCI
8.35
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Aging (P01AG004875, R01AG013925, R33AG061456, R37AG013925, P01AG062413)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK128552)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (K01AR070241, R01AR027065)
Topics
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
cellular senescence, aging, endocrine disorders, senolytics, senescence-associated secretory phenotype, osteoporosis, metabolic syndrome, type 2 diabetes, healthspan, age-related chronic diseases
MeSH terms
Aging, Animals, Endocrine System Diseases, Humans, Risk Factors, Cellular Senescence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review